Eli Lilly Acquires Three Key Vaccines Portfolio for Nearly $4 Bn
Advertisement
LimmaTech Biologics is developing vaccines targeting bacterial infections that are increasingly resistant to antibiotics.
Eli Lilly & Co. has agreed to acquire three vaccine developers, Curevo Inc., LimmaTech Biologics AG and Vaccine Company Inc, in a deal valued at about $3.8 billion.
The U.S.-based pharmaceutical company plans to use the acquisitions to expand its vaccines and infectious disease portfolio, according to a report in The Wall Street Journal, which cited a total transaction value of roughly $4 billion.
Curevo’s lead product candidate is amezosvatein, a shingles vaccine designed to boost efficacy and reduce side effects compared with existing shots, while also addressing hesitancy around receiving a second dose.
LimmaTech Biologics is developing vaccines targeting bacterial infections that are increasingly resistant to antibiotics. Its pipeline includes candidates against Neisseria gonorrhoeae and Chlamydia trachomatis, which cause the sexually transmitted infections gonorrhoea and chlamydia, as well as Staphylococcus aureus, which can lead to serious staph infections.
Vaccine Company’s lead program focuses on nanoparticle-based technologies aimed at preventing Epstein–Barr virus (EBV), which is associated with mononucleosis and an elevated long-term risk of multiple sclerosis.
"These acquisitions reflect a deliberate strategy to prevent disease at its source rather than treat its consequences," Daniel M. Skovronsky, M.D., Ph.D., chief scientific and product officer, and president, Lilly Research Laboratories said.
"Decades of evidence now link common infections to diseases that potentially emerge years later, including neurological disease, cancer and infertility. And as antimicrobial resistance erodes our ability to treat bacterial infections, vaccines are increasingly the only path to prevention. Combining these companies' platforms and teams with Lilly's global scale positions us to change that trajectory."
Stay tuned for more such updates on Digital Health News
